Sign in
CRSP-CRISPR THERAPEUTICS AG

CRISPR Therapeutics Reports Narrower Q4 Loss, Stock Surges as Casgevy Shows Promise for Future Growth

Monday

17 February, 2025

CRISPR Therapeutics is navigating a transformative year, reporting a narrower Q4 loss and a promising debut for its first revenue-generating gene therapy, Casgevy. With a solid cash position and ambitious plans for growth, can this biotech leader turn challenges into opportunities?

article image for CRSP

Article Impact Score

0
50
100
Under­perform
Bear­ish
Neu­tral
Bull­ish
Out­perform
85
Key Takeaways
  • CRISPR Therapeutics is a leader in gene editing with a strong track record of exceeding earnings expectations.
  • The approval of Casgevy represents a major achievement, with anticipated sales of $10 million this quarter.
  • The company is expanding its pipeline to include treatments for sickle cell disease and next-gen CAR-T therapies.
  • With $1.90 billion in cash, CRISPR is well-positioned for future growth and innovation.
  • Investors are optimistic about the company's upcoming developments and potential in the biotech field.
More on CRISPR THERAPEUTICS AG
Read more insights on CRISPR THERAPEUTICS AG

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial
home-footer-logo

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.